161P - Metabolic factors were associated with the outcome of gemcitabine-treated patients with advanced NSCLC identified by high through-put liquid-chip

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Anticancer agents
Translational Research
Non-Small Cell Lung Cancer
Basic Principles in the Management and Treatment (of cancer)
Biological Therapy
Presenter Zhen-Yu Ding
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors Z. Ding, Z. Liu, X. Zou, L. Dai
  • Cancer Center, West China Hospital, Huaxi, Sichuan University, 610041 - Chengdu/CN



Gemcitabine is one of the most frequently prescribed chemotherapy regimen for patients with advanced NSCLC. There is an urgent but un-met need to develop the prognostic biomarkers for the regimen. We reasoned the metabolic factors might be associated with the prognosis of this regimen.


This study was a prospective, exploratory, registered trial (ChiCTR-POC-15007228). Newly-diagnosed, chemotherapy-naïve patients with advanced NSCLC who were prescribed with gemcitabine chemotherapy (cisplatin or carboplatin) were enrolled. Blood was sampling before the initiation of the chemotherapy. The metabolic factors were determined by liquid-chip (FLEXMAP 3D). The ERCC1 and RRM1 were detected by commercially available real-time PCR kits. The sera gemcitabine concentration was measured with HPLC. The primary end-point was OS.


From March 2012, to December 2013, 59 patients were enrolled. 13 metabolic factors (C-peptide, Ghrelin, GIP, GLP-1, Glucagon, IL-6, Insulin, Leptin, MCP-1, PP, PYY, TNF-α, Amylin) were measured and most of them could be detected in the peripheral blood. C-peptide (25.8 and 15.7 months, p = 0.04) and Insulin (25.8 and 14.9 months, p = 0.01) were found to be related to poor prognosis. The prognostic value remained in multi-variate COX regression model (HR = 2.20 and 2.37 respectively). However, neither ERCC1 (p = 56), or RRM1 (p = 0.70), nor gemcitabine concentration (p = 0.17) was related to the survival.


C-peptide and insulin are novel and promising biomarkers for gemcitabine treatment and warrant further validation.

Clinical trial identification


Legal entity responsible for the study





All authors have declared no conflicts of interest.